TherapeuticsMD Analyst Ratings
TherapeuticsMD Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/11/2023 | -11.35% | Cantor Fitzgerald | → $5 | Reinstates | → Neutral |
| 07/13/2022 | -82.27% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 77.3% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -82.27% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -55.67% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -46.81% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -78.72% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -11.35% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 165.96% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | 6.38% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 378.72% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 95.04% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月11日 | -11.35% | 康託·菲茨傑拉德 | →$5 | 恢復 | →中性 |
| 07/13/2022 | -82.27% | 康託·菲茨傑拉德 | →$1 | 重申 | →中性 |
| 06/07/2022 | 77.3% | HC Wainwright公司 | →$10 | 評級下調 | 購買→中性 |
| 05/06/2022 | -82.27% | 康託·菲茨傑拉德 | $5→$1 | 評級下調 | 超重→中性 |
| 03/11/2022 | -55.67% | HC Wainwright公司 | $3→$2.5 | 維護 | 買 |
| 2021年11月12日 | -46.81% | HC Wainwright公司 | $4→$3 | 維護 | 買 |
| 08/07/2020 | -78.72% | 傑富瑞 | $1.25→$1.2 | 評級下調 | 持有→表現不佳 |
| 2020/05/19 | - | 摩根大通 | 評級下調 | 超重→中性 | |
| 05/07/2020 | -11.35% | HC Wainwright公司 | $6→$5 | 重申 | →購買 |
| 04/16/2020 | 165.96% | Stifel | $14→$15 | 維護 | 買 |
| 02/21/2020 | 6.38% | HC Wainwright公司 | $7→$6 | 維護 | 買 |
| 2018年08月14日 | 378.72% | 康託·菲茨傑拉德 | $26→$27 | 維護 | 超重 |
| 2018年06月15日 | 95.04% | 摩根大通 | →$11 | 開始承保 | →超重 |
What is the target price for TherapeuticsMD (TXMD)?
TreateuticsMD(TXMD)的目標價格是多少？
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on January 11, 2023. The analyst firm set a price target for $5.00 expecting TXMD to fall to within 12 months (a possible -11.35% downside). 5 analyst firms have reported ratings in the last year.
康託·菲茨傑拉德於2023年1月11日報道了TreateuticsMD(納斯達克：TXMD)的最新目標價。這家分析公司將目標價定為5美元，預計TXMD將在12個月內降至(可能下跌11.35%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for TherapeuticsMD (TXMD)?
最近分析師對TreateuticsMD(TXMD)的評級是多少？
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD their neutral rating.
對TreateuticsMD(納斯達克代碼：TXMD)的最新分析師評級由坎託·菲茨傑拉德提供，TreateuticsMD的評級為中性。
When is the next analyst rating going to be posted or updated for TherapeuticsMD (TXMD)?
下一次分析師對TreateuticsMD(TXMD)的評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on January 11, 2023 so you should expect the next rating to be made available sometime around January 11, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查看公共財務報表，與TreeuticsMD的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。TreeuticsMD的上一次評級是在2023年1月11日提交的，所以你應該預計下一次評級將在2024年1月11日左右提供。
Is the Analyst Rating TherapeuticsMD (TXMD) correct?
分析師對TreeuticsMD(TXMD)的評級正確嗎？
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $5.64, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的治療MD(TXMD)評級為A，目標價在0.00美元至5.00美元之間。TreateuticsMD(TXMD)目前的交易價格為5.64美元，超出了分析師的預測範圍。